Printer Friendly

HAUSER EXPANDS AIDS RELATED RESEARCH WITH THIRD NIH GRANT

 BOULDER, Colo., Oct. 4 /PRNewswire/ -- Hauser Chemical Research Inc. (NASDAQ: HAUS) announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health (NIH). This grant will allow Hauser to expand the scope of proprietary artemisinin derivatives for the treatment of opportunistic parasitic infections in immunocompromised patients. The value of the grant is $500,000. This award follows Hauser's previous NIH Phase I SBIR grant to produce and evaluate artemisinin derivatives and its contract for process development and production of michellamine B, a natural compound under study by NIH for anti-HIV activity.
 According to Dean P. Stull, Hauser chief executive officer, "We are very pleased with this NIH grant which will help accelerate our efforts to commercialize our artemisinin derivatives. The grant also demonstrates the importance that NIH places on treatment of opportunistic parasitic diseases in AIDS patients."
 Artemisinin, a naturally occurring chemical, is isolated by Hauser from the herb Artemisia annua. The plant has been used for years in China to treat malaria, a parasitic infection. Hauser has developed derivatives of artemisinin and is sponsoring laboratory research on their use in combating opportunistic parasitic infections, such as toxoplasmosis and cryptosporidiosis in humans and animals. Parasitic infections are a major cause of death in AIDS and other immunocompromised patients.
 Hauser's Phase I SBIR Grant, completed last Fall, demonstrated promising results with a number of new proprietary derivatives of artemisinin. Work under this new Phase II grant will focus on semi- synthesis of additional new derivatives and preclinical screening, toxicology and efficacy studies to be carried out at the University of Colorado Health Sciences Center and Utah State University. Hauser has been working with artimisinin and its derivatives since 1985.
 Hauser is the leader in specialty products from natural sources using its proprietary technologies. These products include natural flavor extracts for the food and beverage industry as well as natural compounds for pharmaceutical, cosmetic and veterinary applications. Recently Hauser announced that it has received R&D Magazine's 1993 R&D 100 Award for its unique process for the production of paclitaxel (Taxol). The company also provides interdisciplinary laboratory testing services, chemical engineering services and contract research and development through Hauser Laboratories. The company is based in Boulder.
 -0- 10/4/93
 /CONTACT: Dean P. Stull, chief executive officer, or Investor Relations Department, 303-443-4662/
 (HAUS)


CO: Hauser Chemical Research ST: Colorado IN: CHM SU:

NY-MF -- LA005 -- 8341 10/04/93 12:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 4, 1993
Words:422
Previous Article:ORIOLE HOMES REPORTS THIRD QUARTER SALES DATA; VALUE OF NEW SALES CONTRACTS UP 32 PERCENT; BACKLOG OF UNDELIVERD HOUSING UP 29 PERCENT
Next Article:THE CANTON INDUSTRIAL CORP. SIGNS STOCK PURCHASE AGREEMENT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters